RecallRadar

FDA Drug recall D-0003-2021

Buprenorphine Transdermal System 5 mcg/hour, 4 transdermal systems/4 disposal units per carton, Rx Only, Manufactured by: 3M Drug Delivery…

On 2020-10-07 the FDA classified a Class II recall of Buprenorphine Transdermal System 5 mcg/hour, 4 transdermal systems/4 disposal units per carton, Rx Only, Manufactured by: 3M Drug Delivery… by Teva Pharmaceuticals Usa, citing failed Stability Specifications: Below specification result for buprenorphine release rate.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0003-2021
ClassificationClass II
Statusterminated
Initiated2020-09-04
Published2020-10-07
Last updated2026-09-13 11:52 UTC
CompanyTeva Pharmaceuticals Usa
DistributionUS

Product

Buprenorphine Transdermal System 5 mcg/hour, 4 transdermal systems/4 disposal units per carton, Rx Only, Manufactured by: 3M Drug Delivery Systems, 19901 Nordhoff street, Northridge, CA 91324 USA, Manufactured for: Teva Pharmaceuticals USA Inc., North Wales, PA 19454, carton NDC: 0093-3656-40, patch NDC: 0093-3656-21.

Reason

Failed Stability Specifications: Below specification result for buprenorphine release rate.

Identifiers

ndc0093-3656-40
ndc0093-3239-40
ndc0093-3657-40
ndc0093-3658-40
ndc0093-3659-40
ndc0093-3656-21
code_infoLot # 190017, exp. 02/2021; 190161, exp. 08/2021

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0003-2021%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.